Treatment of chronic hepatitis B virus infection using small molecule modulators of nucleocapsid assembly: recent advances and perspectives
L Yang, F Liu, X Tong, D Hoffmann, J Zuo… - ACS infectious …, 2019 - ACS Publications
On the basis of the recent advance of basic research on molecular biology of hepatitis B
virus (HBV) infection, novel antiviral drugs targeting various steps of the HBV life cycle have …
virus (HBV) infection, novel antiviral drugs targeting various steps of the HBV life cycle have …
Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies
Y Ren, Y Ma, S Cherukupalli, JE Tavis… - European Journal of …, 2020 - Elsevier
Hepatitis B is a vaccine-preventable, but potentially life-threatening liver infection caused by
the Hepatitis B virus (HBV). It represents an important health burden, with 257 million active …
the Hepatitis B virus (HBV). It represents an important health burden, with 257 million active …
Interplay between the hepatitis B virus and innate immunity: from an understanding to the development of therapeutic concepts
S Faure-Dupuy, J Lucifora, D Durantel - Viruses, 2017 - mdpi.com
The hepatitis B virus (HBV) infects hepatocytes, which are the main cell type composing a
human liver. However, the liver is enriched with immune cells, particularly innate cells (eg …
human liver. However, the liver is enriched with immune cells, particularly innate cells (eg …
Discovery of small molecule therapeutics for treatment of chronic HBV infection
S Feng, L Gao, X Han, T Hu, Y Hu, H Liu… - ACS infectious …, 2018 - ACS Publications
The chronic infection of hepatitis B virus (HBV) inflicts 250 million people worldwide
representing a major public health threat. A significant subpopulation of patients eventually …
representing a major public health threat. A significant subpopulation of patients eventually …
Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A–H clinical isolates and core site-directed mutants in vitro
T Verbinnen, Y Tan, G Wang… - Journal of …, 2020 - academic.oup.com
Objectives To characterize antiviral activity of the capsid assembly modulator (CAM-N) JNJ-
56136379 against HBV genotypes and variants carrying amino acid substitutions in the core …
56136379 against HBV genotypes and variants carrying amino acid substitutions in the core …
Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype AH clinical isolates and core site-directed mutants in vitro
JM Berke, Y Tan, T Verbinnen, P Dehertogh… - Antiviral research, 2017 - Elsevier
The HBV core protein represents an attractive target for new antiviral therapies due to its
multiple functions within the viral life-cycle. Here, we report the antiviral activity of the capsid …
multiple functions within the viral life-cycle. Here, we report the antiviral activity of the capsid …
Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
S Alonso, AR Guerra, L Carreira, JÁ Ferrer… - BMC …, 2017 - Springer
Abstract Background Hepatitis B virus (HBV) chronic infection affects up to 240 million
people in the world and it is a common cause of cirrhosis and hepatocellular carcinoma …
people in the world and it is a common cause of cirrhosis and hepatocellular carcinoma …
New viral and immunological targets for hepatitis B treatment and cure: a review
JE Arends, FI Lieveld, S Ahmad… - Infectious Diseases and …, 2017 - Springer
Although current therapies can be successful at suppressing hepatitis B viral load, long-term
viral cure is not within reach. Subsequent strategies combining pegylated interferon alfa with …
viral cure is not within reach. Subsequent strategies combining pegylated interferon alfa with …
Гепатит С стал излечим. Гепатит В-следующий?
ВП Чуланов, АП Зуева, ДС Костюшев… - Терапевтический …, 2017 - cyberleninka.ru
Хронический гепатит В (ХГВ) и хронический гепатит С (ХГС)—главные причины
цирроза и рака печени, от которых в мире ежегодно умирают более 1 млн человек. В …
цирроза и рака печени, от которых в мире ежегодно умирают более 1 млн человек. В …
Hepatitis C can be cured: will hepatitis B become next?
VP Chulanov, AP Zueva, DS Kostyushev… - Terapevticheskii …, 2017 - ter-arkhiv.ru
Chronic hepatitis B (CHB) and C (CHC) are one of the leading causes of cirrhosis and liver
cancer with over a million of people dying annually from their consequences. In Russia CHB …
cancer with over a million of people dying annually from their consequences. In Russia CHB …